Related references
Note: Only part of the references are listed.Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
David E. Bernstein et al.
DIGESTIVE DISEASES AND SCIENCES (2022)
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice
Hidenori Toyoda et al.
HEPATOLOGY (2021)
Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
Pei-Yuan Su et al.
PEERJ (2021)
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study
Mina S. Farag et al.
JOURNAL OF VIRAL HEPATITIS (2021)
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study
Pietro Lampertico et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population
Carlo Garofalo et al.
KIDNEY INTERNATIONAL (2017)
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
Eiichi Ogawa et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L. Y. Chan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
An Association between Body Mass Index and Estimated Glomerular Filtration Rate
Ryuichi Kawamoto et al.
HYPERTENSION RESEARCH (2008)